Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINTRAMUSCULARGeneric

FLULAVAL 2025/2026

influenza virus vaccine

Standard Dose
Refer to label-specific dosage instructions.
Max Dose
See product label
Primary Use
Marketed suspension containing INFLUENZA A VIRUS A/CROATIA/10136RV/2023 X-425A (H3N2) ANTIGEN (UV, FORMALDEHYDE INACTIVATED), INFLUENZA A VIRUS A/VICTORIA/4897/2022 IVR-238 (H1N1) ANTIGEN (UV, FORMALDEHYDE INACTIVATED), INFLUENZA B VIRUS B/AUSTRIA/1359417/2021 BVR-26 ANTIGEN (UV, FORMALDEHYDE INACTIVATED).
Summary

Product profile Marketed suspension containing INFLUENZA A VIRUS A/CROATIA/10136RV/2023 X-425A (H3N2) ANTIGEN (UV, FORMALDEHYDE INACTIVATED), INFLUENZA A VIRUS A/VICTORIA/4897/2022 IVR-238 (H1N1) ANTIGEN (UV, FORMALDEHYDE INACTIVATED), INFLUENZA B VIRUS B/AUSTRIA/1359417/2021 BVR-26 ANTIGEN (UV, FORMALDEHYDE INACTIVATED).

Dose form and route SUSPENSION · INTRAMUSCULAR

Structured Monograph

Clinical summary

Product profile Marketed suspension containing INFLUENZA A VIRUS A/CROATIA/10136RV/2023 X-425A (H3N2) ANTIGEN (UV, FORMALDEHYDE INACTIVATED), INFLUENZA A VIRUS A/VICTORIA/4897/2022 IVR-238 (H1N1) ANTIGEN (UV, FORMALDEHYDE INACTIVATED), INFLUENZA B VIRUS B/AUSTRIA/1359417/2021 BVR-26 ANTIGEN (UV, FORMALDEHYDE INACTIVATED). Dose form and route SUSPENSION · INTRAMUSCULAR

Monitoring

  • • Review the product-specific label before prescribing.

Interaction Notes

  • • Interaction data should be confirmed against the corresponding label.